A pilot study to investigate the efficacy, feasibility and safety of once weekly injection of exenatide-LAR in addition to standard diabetes care on blood glucose control in indigenous Australians with type 2 diabetes living in remote communities

Trial Profile

A pilot study to investigate the efficacy, feasibility and safety of once weekly injection of exenatide-LAR in addition to standard diabetes care on blood glucose control in indigenous Australians with type 2 diabetes living in remote communities

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Oct 2016

At a glance

  • Drugs Exenatide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms LOWER-SUGAR
  • Sponsors AstraZeneca
  • Most Recent Events

    • 25 Oct 2016 Planned number of patients changed from 50 to 40.
    • 25 Oct 2016 Planned End Date changed from 1 Jun 2017 to 31 Aug 2017.
    • 25 Oct 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top